NasdaqHealth CareBiological Products, (No Diagnostic Substances)BOTHELL, WA

LeonaBio, Inc. LONA

Ask your AI

The reported share count looks too low next to the company’s average share countCIK 1620463

Insider trades, 12 mo

1 buy · 10 sells

$99.4K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

19.4% of shares · 3 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q2 2026

What changed in LeonaBio, Inc.'s latest quarterly report, compared with the one before.

Filed Aug 14, 2026 · Quarter ended Jun 30, 2026

Compared with the 10-Q for the quarter ended Mar 31, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in LeonaBio, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

11 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Oct 26, 2026. Insiders have two business days to file.

Recent insider trades

David J. Portman 10% owner	Oct 26 Form 4 ↗	Buy	+$9.9B 3.15M sh @ $3,149.47	-25.7%
Robert Renninger CHIEF FINANCIAL OFFICER	Mar 4 Form 4 ↗	Sale	−$4,865 906 sh @ $5.37	-52.1%
Mark Worthington GENERAL COUNSEL and CCO	Mar 4 Form 4 ↗	Sale	−$7,131 1,328 sh @ $5.37	-52.1%
Church Kevin CHIEF SCIENTIFIC OFFICER	Mar 4 Form 4 ↗	Sale	−$7,298 1,359 sh @ $5.37	-52.1%
Martin Javier San CHIEF MEDICAL OFFICER	Mar 4 Form 4 ↗	Sale	−$9,236 1,720 sh @ $5.37	-52.1%

All LONA insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

1.83M shares

29 funds report LONA. Values checked against market prices.

Funds own 81% of shares (Q2 2026)

44 funds hold the stock.

Q3 2026: 19% · 5,560 of ~8,900 funds reported so far

Q3 202543%
Q1 202673%
Q2 202681%
Q3 2026 (so far)19%

Q3 2026. 3 new, 3 added to, 7 trimmed, 18 exited since Q2 2026.

Top 13F holders
#
1	Kalehua Capital Management LLC 13F ↗	393,701	$1.4M	-50.0%
2	Spruce Street Capital LP 13F ↗	393,701	$1.4M	unchanged
3	Vanguard Capital Management LLC 13F ↗	275,233	$982.6K	unchanged
4	Propel Bio Management, LLC 13F ↗	149,279	$532.9K	unchanged
5	Simplify Asset Management Inc. 13F ↗	149,279	$532.9K	unchanged
6	Landscape Capital Management, LLC 13F ↗	99,109	$353.8K	New
7	Geode Capital Management, LLC 13F ↗	85,336	$304.8K	+6.1%
8	BlackRock, Inc. 13F ↗	78,059	$278.7K	-1.4%
9	Renaissance Technologies LLC 13F ↗	56,966	$203.4K	-26.4%
10	Vanguard Fiduciary Trust Co 13F ↗	42,814	$152.8K	unchanged

Download CSV Every fund that holds LONA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Recent congressional trades

Chris Jacobs R House · NY	Purchase	$1,001 - $15,000 CL TRUST > LDJ FAM INV LLC > Parametric	Dec 12 → Jan 20 ↗ 39d	-178.3%
Chris Jacobs R House · NY	Sale	$1,001 - $15,000 CL TRUST > LDJ FAM INV LLC > Parametric	Nov 8 → Dec 12 ↗ 34d	-185.8%
Chris Jacobs R House · NY	Purchase	$1,001 - $15,000 CL TRUST > LDJ FAM INV LLC > Parametric	Jul 18 → Sep 9 ↗ 53d late	-186.9%

All 3 trades →Free on every plan.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What LeonaBio, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What LeonaBio, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2025	34	—	1.72M	$7.6M
Q4 2025	42	+8	6.21M	$46.7M
Q1 2026	40	-2	6.85M	$70.1M
Q2 2026	44	+4	7.67M	$70.4M
Q3 2026	29	-15	1.83M	$6.5M

Each point is a quarter-end, from Q3 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (04746L203). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes16 in 12 mo 8-K events2 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 1 in 12 mo Executive pay2 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history4 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: LeonaBio, Inc.
Address: 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA 98011
Phone: (425) 620-8501
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Listed as: LONA (Nasdaq)
Former names: Athira Pharma, Inc. (until 2026); M3 Biotechnology, Inc. (until 2019)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$3.47−$0.26 (−6.97%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $3.47 · High $6.43Nov 13, 2026

Aug 13, 2026Low $2.87 · High $8.17Nov 13, 2026

Nov 13, 2025Low $2.87 · High $11.68Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.